---
title: "ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290690105.md"
description: "The company is anticipating a planned reduction of around 17% in its workforce, with estimated annual savings of about $10 million. This move is aimed at increasing the company's financial flexibility. Their main focus is on meeting upcoming regulatory and clinical goals, such as submitting the LOTIS-5 sBLA and releasing full LOTIS-7 data by the end of the specified time frame."
datetime: "2026-06-24T11:32:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290690105.md)
  - [en](https://longbridge.com/en/news/290690105.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290690105.md)
generator: "portal-rs"
---

# ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities

The company is anticipating a planned reduction of around 17% in its workforce, with estimated annual savings of about $10 million. This move is aimed at increasing the company's financial flexibility. Their main focus is on meeting upcoming regulatory and clinical goals, such as submitting the LOTIS-5 sBLA and releasing full LOTIS-7 data by the end of the specified time frame.

### Related Stocks

- [ADCT.US](https://longbridge.com/en/quote/ADCT.US.md)

## Related News & Research

- [ADC Therapeutics highlights ZYNLONTA growth opportunity in corporate presentation](https://longbridge.com/en/news/298617019.md)
- [ADCT: ZYNLONTA's clinical advances and label expansion aim to drive U.S. revenue beyond $600M](https://longbridge.com/en/news/298687077.md)
- [ADCT: ZYNLONTA shows high response rates and regulatory momentum in DLBCL and lymphoma studies](https://longbridge.com/en/news/298749364.md)
- [IPH: Key late-stage data and partnerships position the pipeline for major milestones and growth](https://longbridge.com/en/news/298965815.md)
- [IMNM: Filed NDA for varegacestat and innovative ADC pipeline signal strong oncology momentum](https://longbridge.com/en/news/298941431.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**